Nuwellis reports Q1 EPS (69c) vs ($24.11) last year

Reports Q1 revenue $1.904M vs $1.857M last year. “We are encouraged by the strategic progress we’re making in expanding access to Aquadex therapy, particularly as more hospitals explore outpatient use,” said John Erb, Chairman of the Board and Interim Chief Executive Officer of Nuwellis (NUWE). “With higher reimbursement rates now in effect and a growing base of clinical support, we believe we are well-positioned to expand adoption across both inpatient and outpatient environments in 2025.”